Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
Date:2/16/2010

CRANBURY, N.J., Feb. 16 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the fourth quarter and full year 2009.  The Company also provided an update on advancements in its product pipeline related to its key strategic priorities for 2010.  Additionally, the Company stated that it believes it is well positioned to achieve its key milestone of completing enrollment for its Phase 3 study of Amigal (migalastat HCl) to support approval in the U.S. (Study 011) by year end.

Fourth Quarter and Full-Year 2009 Financials Summary

Amicus announced net income attributable to common stockholders of $1.45 per share for the three months ended December 31, 2009. For the year ended December 31, 2009, the net loss attributable to common stockholders was $0.29 per share. As of December 31, 2009, cash, cash equivalents, and marketable securities totaled $78.2 million.

John F. Crowley, Chairman and CEO of Amicus Therapeutics stated, "We are very pleased with the significant progress we made advancing Amigal into Phase 3 in 2009, and we expect to continue this momentum in 2010.  We are confident in the likelihood of success for Amigal and are excited we have the potential to bring to market the first oral treatment to patients with Fabry disease."  

Key Strategic Priorities

The Company reaffirmed its three key strategic priorities for 2010: Phase 3 development of migalastat HCl for Fabry disease, advancing chaperone-ERT combina
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  BC Technical, ... Solutions, has acquired Eclipse Systems, a Nuclear Imaging ... solutions. As part of their ongoing vision to ... an affordable rate, BC Technical continues to expand ... BC Technical to add valuable resources and knowledge ...
(Date:3/2/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... 2014. Total revenues were $4.3 million for the three ... months ended December 31, 2013.  Net loss was $5.9 ... as compared to a net loss of $5.1 million ... million and net loss was $22.1 million for the ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
(Date:3/3/2015)... March 03, 2015 HealthCarePoint ... networking-technology corporation, announced today that it has completed ... Clinical Data Interchange Standards Consortium (CDISC). HCP will ... to standardize knowledge-based training and certifications globally. HCP’s ... and web support as well as development of ...
(Date:3/3/2015)... Salt Lake City, UT (PRWEB) March 03, 2015 ... is an innovative, user-friendly website that focuses ... wilderness therapy, therapeutic boarding schools, and addiction treatment ... Additionally, all residential interventions on the site ... assessments, anxiety, ADHD, autism spectrum disorders, severe learning ...
(Date:3/2/2015)... March 02, 2015 Calvary Hospital ... their Brooklyn Satellite in Lutheran Medical Center, with ... award must demonstrate excellence through clinical expertise as ... expected to go above and beyond to make ... with patients and their families. Award recipients are ...
(Date:3/2/2015)... Dr. David Knepp, a leading chiropractor with ... Doctors on Liens to bring his medical team’s ... personal injury victims to have access to multiple specialists ... basis. However, San Diego Chiropractic Group does ... pain management physician, massage, and acupuncture to help aid ...
(Date:3/2/2015)... 1% for the Planet , one of ... over 25 new business members at this year’s Expo West ... 1% for the Planet welcomes them and more, including Boulder ... nut butter line. , Food - how we grow ... continues to be a complex environmental issue throughout the country ...
Breaking Medicine News(10 mins):Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:All Kinds of Therapy – New Website for Behavioral Health and Substance Abuse Treatment Launches Today 2Health News:Calvary Hospital Honors Peter Acerios, RN, with Daisy Award 2Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 2Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 3
... Testing for the presence of specific cancer protein ,fingerprints, ... a useful means of identifying a subgroup whose tumors ... drug erlotinib, especially when other testing methods are unavailable, ... Lung Cancer Conference in Geneva, Switzerland. Erlotinib is ...
... finds , FRIDAY, April 30 (HealthDay News) -- A shared ... spouses of kidney dialysis patients are at increased risk for ... were surprised to find that the risk of developing chronic ... as high as it is for blood relatives of these ...
... treatment decisions and political advocacy, study finds , FRIDAY, April ... than just their parents in their corner, with a new ... in the lives of kids with the developmental disorder. , ... the care of youngsters with autism. In fact, the report ...
... are known to have a higher risk of cancer, compared ... immunosuppressive drugs to prevent organ rejection. Results published today from ... to increase this cancer risk. Evaluating data from 1983 ... 481 patients over 20 years - providing the strongest evidence ...
... ... ABBY Award winners: A-Life Medical, Inc.; Specialists On Call, Inc.; and VQ OrthoCare, as ... Novasys Medical, Inc. The winners were announced at ABL Organization’s 12th Annual Innovations in ... ...
... with 2 men who had not been helped with ... Injecting a local anesthetic next to a group of ... is a fast-acting and effective way to treat combat-related ... , The 10-minute procedure, called a stellate ganglion block, ...
Cached Medicine News:Health News:Blood test may identify lung cancer patients likely to respond to erlotinib 2Health News:Why Spouses of Dialysis Patients Get Kidney Disease Too 2Health News:Grandparents Play Vital Role for Autistic Children 2Health News:Grandparents Play Vital Role for Autistic Children 3Health News:Cancer risk for kidney transplant 2Health News:ABBY Winners Announced & Honored with 2010 Innovations in Healthcare(SM) Awards 2Health News:ABBY Winners Announced & Honored with 2010 Innovations in Healthcare(SM) Awards 3Health News:Local Anesthetic May Relieve PTSD Symptoms 2
Helveston tying forceps, standard with smooth jaws. For 4-0 to 6-0 sutures....
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Medicine Products: